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Background/aim: H. pylori infection and vitamin B12 (vB12) deficiency have high prevalence rates among Palestinians. It was observed
that most people who suffered from vB12 deficiency were positive for H. pylori.
Materials and methods: The correlation between H. pylori infection and vB12 deficiency was investigated in a representative segment of
the Palestinian population. ELISA was used to determine levels of vitamin B12 (vB12) and anti-H. pylori IgA in sera from 238 participants
from Al-Khalil district (Hebron), Palestine.
Results: There was a strong negative Pearson’s correlation coefficient (r = –0.45; P = 0.00001) between levels of anti-H. pylori IgA and
vB12 levels in sera drawn from 238 participants (133 patients and 105 control subjects). Two important contaminating variables were
identified in this study: healthy control subjects with elevated anti-H. pylori IgA titers and vB12-deficient patients testing negative for
anti-H. pylori IgA antibodies. The exclusion of the sources of contamination resulted in a stronger negative correlation; r = –0.58 (P =
0.00001).
Conclusion: The study provided a good screening system that may predict vB12 deficiency before its actual manifestation. If not treated,
asymptomatic subjects showing increased anti-H.pylori IgA titers (>15 NTU/mL) are likely to be at risk of developing vB12 deficiency.
Key words: Helicobacter pylori, vitamin B12 deficiency, cobalamin, gastroenteritis, correlation, baseline

1. Introduction
Helicobacter pylori infections induce vigorous systemic
and mucosal humoral responses that are predominantly
mediated by IgA, IgG, and IgM. These immunoglobulins
are detectable in sera, gastric aspirates, or stomach extracts
(1,2). Humoral immunity against H. pylori can effectively
prevent infection and reduce colonization but does not
lead to eradication of H. pylori-induced gastritis (2).
Absorption of dietary cobalamin (vitamin B12; vB12)
depends on several factors, including acid-dependent
deproteinization of vB12. Only free vB12 can form a complex
with the intrinsic factor (IF). The vB12–IF complex is then
absorbed by mucosal cells via its specific receptor (cubilin)
in a calcium-dependent fashion. Gastric parietal cells are
responsible for production of both hydrochloric acid and
IF. Absorbed vB12 is then stored in the liver.
Some H. pylori patients develop autoantibodies
directed against gastric parietal H+/K+-ATPase cells
(APCAs), resulting in achlorhydria and increased
infection with H. pylori, which in turn contributes
to gastric damage and atrophy of the corpus (2).
* Correspondence: bargsam@yahoo.com

Autoimmunity may destroy parietal cells that are
responsible for hydrochloric acid and IF production,
resulting in achlorhydria and failure to deproteinize vB12
and/or failure to produce IF. Consequently, the vB12–IF
complex fails to form, leading to malabsorption of vB12
and, potentially, to pernicious anemia. Hence, patients
diagnosed with vB12 deficiency as a result of APCAs
or anti-IF antibodies were excluded, since their vB12
deficiency cannot be directly and solely attributed to H.
pylori infection (3–6; see Section 2.2).
In this work, we investigated the correlation between
serum anti-H. pylori IgA antibodies and vB12. The role of
contaminating variables on this correlation was explored
as well.
2. Methods and materials
2.1. Patients
Blood samples were collected in 5-mL tubes from 133 vB12deficient patients (60 males, 73 females) and 105 healthy
volunteers (42 males, 63 females), aged 18–50 years (mean,
34.1 years). All 133 patients had vB12 deficiency and
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Helicobacter pylori dyspeptic symptoms such as epigastric
pain, nausea, heartburn, and vomiting (7,8).
Informed consent was obtained from each participant
(patients and healthy volunteers). Interviews and
questionnaires were administered in Arabic to all
participants. Sera were collected starting November 2009
through February 2010.
Collected data regarding smoking habits, age, sex,
symptoms, and causes of vB12 deficiency were recorded for
each participant. A healthy volunteer was defined as one
who did not suffer from disorders or stomach problems,
i.e. absence of gastritis.
2.2. Subject exclusion criteria
In order to focus our research on the relationship between
Helicobacter pylori infection and vB12 deficiency, factors and
cases known to affect the state of vB12 levels were excluded,
with the exception of H. pylori infection. Subjects suffering
from known causes of vB12 deficiency other than H. pylori
infection were excluded and patients suffering from other
chronic diseases that may interfere with the interpretation
of the results of this study were excluded as well.
The exclusion criteria were as follows: age <18 or >50
years; diabetic patients; celiac disease; patients with a
history of (steroid or nonsteroid) antiinflammatory drug,
antiacid, H2-receptor antagonist, or proton pump inhibitor
intake in the previous month; history of treatment of H.
pylori infection; history of drug vB12 intake; patients with
gastrointestinal bleeding, renal failure, liver diseases,
thyroid disorders, autoimmune diseases, previous GI
surgery, folate deficiency, strict vegetarian, neoplasia,
alcohol intake, rheumatoid arthritis, or pregnancy.
2.2.1. Exclusion of vB12-deficient patients showing antiIF activity
The presence of anti-IF antibodies in sera of vB12 deficient
patients was determined using an IF ELISA kit (Alpha S.A/
NV, Belgium), following the manufacturer’s instructions.
Samples were diluted to 1:51, mixed, and 100 μL of each
sample dispensed into a designated microwell. After 30
min of incubation at room temperature, microwells were
washed with diluted washing buffer (1:20) and treated
with 100 μL of conjugate for 30 min. Afterwards, substrate
(100 μL) was added and incubated for 10 min at room
temperature. After adding the stop solution, absorbance
was recorded at 450 nm. A sample was considered negative
when the binding index (BI) was less than 1.0; a sample
was considered positive when BI was >1.0. All positive
subjects were excluded from the study.
2.2.2. Exclusion of subjects showing APCAs
APCAs were determined in sera with a commercial
enzyme immunoassay (Varelisa Parietal Cell Antibodies,
Pharmacia Diagnostics, Germany). All sera samples with
vB12 deficiency (diluted 1:101) were processed according
to manufacturer’s instructions and absorbance was read at
450 nm within 30 min of adding stop solution in reference
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to absorbance recorded at 620 nm. A sample was scored as
negative when the ratio was <1.0, a sample was scored as
equivocal when the ratio ranged between 1.0 and 1.4, and
a sample was positive when the ratio was >1.4. All positive
subjects were excluded from the study.
The decision to exclude these subjects (Sections 2.2.1
and 2.2.2) was based on published literature showing the
presence of APCA among children (9) and diabetic adults
(10) who do not have H. pylori infections. Exclusion was
necessary to have a clear view of the relationship between
H. pylori and vB12 deficiency in the absence of any potential
contaminating factor (including autoimmunity to parietal
cells or IF), and that the results were a true reflection of the
direct relationship of vB12 deficiency to H. pylori infection.
2.3. vB12 deficiency
vB12 was quantified in sera using AxSYM Abbott
automation system (Abbott Laboratories, USA), a method
based on microparticle–enzyme–IF assay; the results were
expressed in pg/mL. The cutoff level for vB12 deficiency is
<200 pg/mL, according to the manufacturer’s instructions.
The following scale was adopted to estimate and define
vB12 level of deficiency among patients: severe deficiency
when the mean vB12 value is <75 pg/mL of serum,
moderate deficiency when the mean vB12 value is between
75 and 150 pg/mL, and mild deficiency when the mean
vB12 ranges from 150 to <200 pg/mL (200 pg/mL being the
cutoff value between deficiency and sufficiency). Normal
vB12 range is >200 to 900 pg/mL (11).
2.4. Quantification of serum anti-Helicobacter pylori IgA
Anti-Helicobacter pylori IgA concentration was determined
in sera samples using an H. pylori IgA ELISA kit (NovaTec
Immundiagnostica; GmbH, Germany) as instructed by
the manufacturer. Microwell plates and reagents were
brought to room temperature (25 °C). Washing buffer
(diluted 1:19 in distilled water) and serum samples (10
μL) were mixed with 0.99 mL IgA diluents. Then 100 μL
of each standard (A, B, C, D) and diluted samples were
placed into their designated wells, covered, and incubated
at 37 °C for 60 min. Microwells were washed 3 times with
300 μL diluted washing buffer. Except for blank wells, 100
μL of Helicobacter pylori anti-IgA conjugate were added to
each well. Plates were incubated in the dark for 30 min at
room temperature. This was followed by another cycle of
washing as above. Substrate (100 μL) was added to each
well (including the blanks), covered, and incubated for 15
min at room temperature (25 °C) in the dark. Stop solution
(100 μL) was added to each well (including the blanks),
covered, and incubated for 15 min at room temperature
in the dark. The blue/orange color of wells was scored for
each well using photometric measurements at 450/620 nm
within 30 min. The scale recommended by manufacturer
was adopted. H. pylori infection was considered reactive if
the mean serum IgA value was >20 NTU/mL, equivocal
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Significant differences (P < 0.05 and P < 0.01; P =
0.00001) were recorded for IgA levels, indicating that
the median IgA for patients (40; range 6–153 NTU/mL
serum) was different from the median for control subjects
(range 0–140 NTU/mL serum) (6). Severe vB12 deficiency
was observed in 4.5% (6/133 patients); moderate vB12
deficiency in 48.9% (65/133). The remaining 62 patients
(46.6%), showed mild vB12 deficiency. Healthy control
subjects had normal vB12 levels, ranging from 212 to 756
pg/mL serum with the exception of one subject, a 35-yearold female that showed vB12 deficiency (187 pg/mL) and
high IgA titer (22 NTU/mL).
The majority of healthy participants (85.7%, 90/105)
had background levels of anti-Helicobacter pylori IgA (0
to 14 NTU/mL). Fifteen control subjects (14.3%; 15/105
including the 35-year-old female with vB12 deficiency) had
IgA titers higher than 15 NTU/mL, ranging from 22 to
140 NTU/mL serum. The vast majority of vB12-deficient
patients (84.2%; 112/133) had IgA titers higher than 20
NTU/mL, while the remaining patients (15.8%; 21/133)
had low levels of IgA (Table). The two groups (15 control
and 22 patient subjects) were viewed as contaminating
factors (Table and Section 3.2.). There was no correlation
between age and vB12 deficiency (r = –0.0495; P = 0.44) nor
between age and IgA titers (r = 0.0207; P = 0.679).
3.2. Correlation between vB12 levels and anti-H. pylori
IgA
Pearson’s correlation coefficient ‘r’ between serum vB12
and anti-H. pylori IgA levels was –0.4809; P = 0.00001 as
determined for all 238 participants (105 controls and 133
patients). However, when 15 control subjects (showing IgA

if the mean serum IgA titer fell between 15 and 20 NTU/
mL, and nonreactive if the mean serum IgA value was <15
NTU/mL (healthy or immune-tolerant).
2.5. Statistical analysis and graphs
Collected data were analyzed using Microsoft Excel (2007)
and the online Social Science Statistics (http://www.
socscistatistics.com/tests/mannwhitney/Default.aspx)
(10). Analyses and calculations included means, standard
deviation, median, upper and lower limits, Mann–Whitney
significant differences between control and patient groups
at P < 0.05 and P < 0.01, and open form P-values.
Correlation analyses were based on Excel Pearson’s R2
and its square root (r), while confidence was determined
using the two-tailed “r” distribution at P < 0.05 and P <
0.01 and open form P-values. Additionally, Pearson’s
correlation levels were analyzed after removing potential
contaminating variables (factors) which included subjects
with abnormal vB12 or abnormal IgA titers and some
outlier values as described in Section 3.

vB 12 (pg/mL) or IgA titers (NTU/mL)

3. Results
3.1. Levels of vB12 and IgA
Levels of vB12 and anti- Helicobacter pylori IgA in sera are
presented in Figure 1 and the Table. Means and medians
for each of the four groups of subjects were obtained. The
median of serum vB12 level for patients (150; range 59–198
pg/mL serum) was significantly different from the median
for the control group (330; range 187–731 pg/mL serum,
P = 0.00001) and the medians were significantly different
at P < 0.05 and P < 0.01 (Mann–Whitney U-test) (Figure
1 and Table).
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Figure 1. Vitamin B12 (vB12; pg/mL) and anti-H. pylori (IgA; NTU/mL) serum
levels. Mean ± standard deviation (SD) among control (vB12-C) or patients
(vB12-P) subjects are presented as shaded bars. Median values for each
category are presented as clear bars. The corresponding lower and upper limits
are given in the inset table. Mann–Whitney test was significant (P < 0.05 and P
< 0.01; P = 0.00001) for vB12 or IgA relative to their control values; see Table.
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Table. Summary table of data statistics: Pearson’s correlation (r) for raw samples.
Data
exclusion

• Raw data

• Removed
15C or 13P

• Removed
15C and 13P
(28 subjects)

• Removed
15C + 13P + 7C

Subject
group

Sample
size (n)

Median

Lower–upper
limits

Mean

SD/SEM

B12-C

105

330¶

187–731

357.5

97.5

IgA-C

105

6

0–140

13.6

23.1

vB12-P

133

150

59–198

151.5

31.6

IgA-P

133

40 Φ

6–153

59

45.7

vB12-C

105/90

335

212–665

362

97.5/92.6

IgA-C

105/90

5

0–14

6

23.1/3.9

vB12-P

133/120

150

59–198

152/152

31.6/31.1

IgA-P

133/120

40

0–153

59/63

45.7/45

vB12-C

105/90

335

212–665

362

97.5/92.6

IgA-C

105/90

5

0–14

6

23.1/3.9

vB12-P

133/120

150

59–198

152/152

31.6/31.1

IgA-P

133/120

40

0–153

59/63

45.7/45

vB12-C

83

326.5

212–665

379

62.8

IgA-C

83

5

0–14

6

3.9

vB12-P

120

155

59–198

161

45.1

IgA-P

120

40

0–153

58

32.2

Φ
¶

Pearson’s
correlation (r)

–0.45*

–0.538*
Or
–0.521*

–0.58*

–0.61*

*Significant correlation at P < 0.05 and P < 0.01; P = 0.00001.
Data exclusion category: exclusion of 15 (15C) control subjects showing IgA titers >15 NTU/mL and/or 13 patients (13P) with IgA titers
<15 NTU/mL. Exclusion of seven additional control (7C) subjects (4th group) with vB12 values (537–665 pg/mL).
Φ, ¶
Mann–Whitney differences at P < 0.05 and P < 0.01; P = 0.00001.

titers >15 NTU/mL) were excluded, a stronger correlation
coefficient was obtained (r = –0.539; P = 0.00001). Upon
the omission of 13 patient subjects showing IgA titers
<15 NTU/mL, the obtained correlation coefficient was r
= –0.521; P = 0.00001. When both contaminating groups
(15 controls and 13 patients) were omitted, the correlation
became stronger (r = –0.579; P = 0.00001). A further
omission of a group of controls (7 subjects) showing high
vB12 concentration (>537 pg/mL serum) a further increase
in correlation was obtained (r = –0.615; P = 0.00001). The
results showed significant Pearson’s correlation both at P <
0.05 and P < 0.01.
4. Discussion
4.1. vB12 stores
The liver is the main vB12 store; it stores 80% of total body
vB12 (2 to 5 mg). Stored vB12 will last an adult individual
for 3–5 years in the absence of significant vB12 intake, or
for 5–6 years when vB12 intake is insufficient. In addition,
vB12 undergoes a daily enterohepatic circulation where 1 to
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10 µg is excreted in bile and reabsorbed (6). Accordingly,
it is expected that only chronic H. pylori infections, not
recently acquired infections, will be associated with
H. pylori-induced vB12 deficiencies. Such a correlation
was demonstrated in this study. The presented results
confirmed that IgA titers were high in 15 control subjects
(14.3%); one of them (a 35-year-old female) showed vB12
deficiency, indicating that H. pylori infection preceded
vB12 deficiency and suggesting that H. pylori infection may
indeed have contributed to vB12 deficiency or caused it.
The results suggest the existence of another mechanism for
the role of H. pylori in vB12 deficiency other than APCAs
or anti-IF antibodies. Although accumulating evidence
suggests that H. pylori infection has a negative effect on the
absorption of vB12 (12), the inhibition of vB12 absorption by
H. pylori infection cannot yet be verified.
4.2. Identification of contaminating variables that
influenced correlation analysis
This study identified and excluded at least five contaminating
factors; these factors would have blurred the correlation

ABU HILU et al. / Turk J Med Sci

IgA NTU/mL serum

between vB12 deficiency and H. pylori. Subjects with antiIF activity or APCAs were therefore excluded, since vB12
in these subjects cannot be directly correlated to H. pylori
infection and would have acted as contaminating variables.
The study was further strengthened by excluding patients
consuming supplementary vB12 or those diagnosed with
other diseases, such as celiac disease. Others were excluded
based on their responses to structured questionnaire and
interviews (see Section 2.2). This study has statistically
confirmed previous observations and suggestions (12–19)
linking vB12 deficiency to H. pylori infection. Kaptan et al.
(15) found H. pylori in 77 (56%) of vB12-deficient patients;
others predicted correlation or a cause–effect relationship
between vB12 deficiency and H. pylori infection, with
possible destruction of parietal cells as a result of H.
pylori infection (10, 21). This study determined the actual
negative state of correlation between the two variables (r
= –0.45; P = 0.00001). The correlation between H. pylori
infections as indicated by serum levels of anti-H. pylori
IgA and vB12 deficiency was affected by contaminating
variables; a fraction of the control group (15/105; 14.3%)
showed high IgA titers, suggesting possible asymptomatic
H. pylori infection. Another contaminating factor appeared
among patient subjects in the form of IgA titers lower than
the cutoff value (<15 NTU/mL serum). The impact of
these factors on correlation was demonstrated when they
were excluded from data before analysis. The omission of
15 contaminating control subjects caused an increase in

165
150
135
120
105
90
75
60
45
30
15
0

correlation (r = –0.538). A similar contribution was made
upon omission of 13 patients showing IgA titers lower
than 15 NTU/mL (r = –0.521). When both contaminating
variables were omitted, a stronger correlation emerged
(r = –0.58). Omission of seven (6.6%) additional control
subjects showing high levels of vB12 (536–731 pg/mL
serum; Figure 2A) increased the correlation coefficient
to r = –0.61. All correlations between vB12 and IgA were
significant; P = 0.00001.
4.3. Anomalies among subjects
Figure 2 illustrates that subjects can be categorized into
one of four clusters based on the combined level of vB12
and anti-H. pylori IgA. Cluster A reflects normal healthy
subjects with high vB12 (>200 pg/mL) and low IgA (<15
NTU/mL). Cluster B contains healthy controls with high
vB12 but with elevated anti-H. pylori IgA (>15 NTU/
mL), which may be indicative of asymptomatic infection
or recent exposure. Among patients with mild vB12
deficiency (>150 but <200 pg/mL), cluster C showed poor
IgA response, whereas cluster D subjects showed high or
exaggerated IgA titers (subcluster D2). Although we do not
have an explanation for these variations, several possible
explanations can be put forward for future considerations.
First, antigenic variations among H. pylori variants may
render the anti-H. pylori IgA determination kit insensitive
to some antigenic variants of H. pylori (18,20–23), i.e. IgA
kit cannot equally detect all H. pylori antigenic variants.
Second, these patients, or some of them, cannot mount
Trends of vB 12 and IgA levels

D2

among subjects

D1

B

A

C
0

100

200

300

400

500

600

700

800

vB 12 pg/mL serum

Figure 2. Scatter blot of all 238 subjects; vB12 was blotted against its cognate IgA
value. The cutoff value for IgA (15 NTU/mL) (y = 15) and the cutoff value for vB12
(x = 200 pg/mL) are indicated. Accordingly, several clusters/trends (A–D) can be
distinguished. A: High vB12 and low IgA (typical normal healthy control subjects),
B: high vB12 and high IgA (possible asymptomatic patients; a potential contaminating
factor, see Section 4), C: low vB12 and low IgA (patients not responding to infection;
another potential contaminating factor), D: low vB12 and moderate or high IgA
(majority of typical patients); D1: normal patients (IgA < 124), D2: a subset of
patients showing exaggerated IgA levels (>144 NTU/mL serum).
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IgA NTU/mL serum

200

Correlation between serum vB 12 and IgA

150
Pearson’s, r =–0.45
P = 0.00001

100
50
0

–50

0

200

400

600

800

vB12 pg/mL serum

Figure 3. Correlation between vB12 levels and H. pylori infection (IgA).
Scatter distribution of vB12 vs. IgA for all 238 subjects. A negative
Pearson’s correlation was established (r = –0.45 for original data; P <
0.05 and P < 0.01; P = 0.00001).

a significant IgA immune response against H. pylori (i.e.
they are immune-tolerant). Third, vB12 deficiency among
cluster C patients, or some of them, was the result of a
factor independent of H. pylori. Exaggerated IgA levels
observed in some patients (Figure 2, D2), may be due to
repetitive exposure to living or dead H. pylori antigens
(e.g., drinking H. pylori-contaminated or chlorinated well
water). Another possibility resides in the potency of the
subject’s immune response to different H. pylori antigenic
variants.
4.4. Incidence and baseline of asymptomatically infected
population
A conclusion regarding the incidence and baseline of an
asymptomatically infected population was calculated to be
approximately 14.3% (15/105) as represented by the high
titer (>15 NTU/mL serum) of anti-H. pylori IgA among
normal control subjects aged 18 to 50 years from the
Hebron area. In an earlier study by Serin et al. (24), 25%
of healthy children were PCR-positive for H. pylori (24).
Since some of the children were only transiently infected
while others may have progressed to become symptomatic
(25), it is likely that the percentage of asymptomatic
subjects will decrease (i.e. <25%); accordingly it is likely
that the baseline falls somewhere above 14.3% and below
25%.
In 9.8% of patients (13/133), IgA level did not predict
the state of H. pylori infection (Figure 2C); IgA titers were
below the cutoff value of the test (15 NTU/mL serum).
Possible antigenic variants of H. pylori or other microbes
may have caused gastritis and cannot be detected by the
IgA test used in this study. Another possibility is that
some subjects (including control subjects) were immunetolerant to the H. pylori-targeted antigen. This category
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of IgA-negative subjects, in addition to false negative test
results among all subjects, will shift the base line to a level
higher than 14.3% when taken into consideration.
Additional studies across a given population are
needed to obtain a realistic profile of the epidemiology of
H. pylori infections.
4.5. Conclusions
Infection with H. pylori was negatively correlated to serum
levels of vB12 and may contribute to this deficiency. If other
categories (e.g., individuals aged <18 and >50) and factors
are to be included in similar future studies, the baseline
of asymptomatically infected healthy subjects may be
significantly higher than 14.3%.
Serum level of anti-H. pylori IgA appears to be a
good indicator of risk of developing vB12 deficiency. It
is our recommendation that subjects showing high IgA
titers should be treated for H. pylori, monitored, and
prophylactically treated for vB12 deficiency. Failure of the
IgA test to predict acute or chronic H. pylori infections
in 9.8% of patients justifies the need for an additional
supplementary or alternative test capable of detecting H.
pylori in these and similar subjects, including apparently
healthy subjects.
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